Cargando…

What is the role of checkpoint inhibitors in neuroendocrine neoplasms?

Detalles Bibliográficos
Autores principales:	Al-Toubah, Taymeyah, Pelle, Eleonora, Strosberg, Jonathan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584236/ https://www.ncbi.nlm.nih.gov/pubmed/33144916 http://dx.doi.org/10.18632/oncotarget.27768

Ejemplares similares

Chemotherapy in Neuroendocrine Tumors
por: Das, Satya, et al.
Publicado: (2021)

Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors
por: Al-Toubah, Taymeyah, et al.
Publicado: (2022)

Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms
por: Al-Toubah, T., et al.
Publicado: (2021)

Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade
por: Al-Toubah, Taymeyah, et al.
Publicado: (2023)

Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors
por: Cives, Mauro, et al.
Publicado: (2020)

Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials
por: Vijayvergia, Namrata, et al.
Publicado: (2020)

HORMONET: a phase II trial of tamoxifen for estrogen/progesterone receptor-positive neuroendocrine tumors
por: Barros, Milton J., et al.
Publicado: (2023)

(177)Lutetium-Dotatate delays decline in quality of life in patients with midgut neuroendocrine tumors
por: Strosberg, Jonathan
Publicado: (2018)

Thymic neuroendocrine neoplasms—what we know, what we don’t know, and what to do about it
por: Lang, Matthias, et al.
Publicado: (2023)

Neuroendocrine neoplasm: Current understanding
por: Lila, AR, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update
por: DeCarli, Kathryn, et al.
Publicado: (2022)

Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
por: Bongiovanni, Alberto, et al.
Publicado: (2021)

Lurbinectedin, a DNA minor groove inhibitor for neuroendocrine neoplasms beyond small cell lung cancer
por: Bhamidipati, Deepak, et al.
Publicado: (2023)

Neuroendocrine neoplasms: a brief overview emphasizing gastroenteropancreatic tumors
por: Lopes, José Manuel
Publicado: (2017)

Better Management for Neuroendocrine Neoplasms: A Complex Task Ahead
por: Coriat, Romain
Publicado: (2021)

Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors
por: Mandriani, Barbara, et al.
Publicado: (2022)

mTOR Inhibitors as Radiosensitizers in Neuroendocrine Neoplasms
por: Exner, Samantha, et al.
Publicado: (2021)

Efficacy of Immune Checkpoint Inhibitors against Advanced or Metastatic Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
por: Park, Eun-Joo, et al.
Publicado: (2022)

Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation
por: Eng, Cathy, et al.
Publicado: (2021)

The Increasing Incidence of Neuroendocrine Neoplasms Worldwide: Current Knowledge and Open Issues
por: Rossi, Roberta Elisa, et al.
Publicado: (2022)

DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors
por: Cives, Mauro, et al.
Publicado: (2019)

Challenges in High-grade Neuroendocrine Neoplasms and Mixed Neuroendocrine/Non-neuroendocrine Neoplasms
por: La Rosa, Stefano
Publicado: (2021)

Exploring the role of survivin in neuroendocrine neoplasms
por: Hanif, Ahmad, et al.
Publicado: (2020)

Mixed Neuroendocrine and Non-Neuroendocrine Neoplasm of Pancreas: What Do We Know, What Have We Learnt?
por: Dhakre, Vijay W., et al.
Publicado: (2023)

Targeted Cancer Therapy: What’s New in the Field of Neuroendocrine Neoplasms?
por: La Salvia, Anna, et al.
Publicado: (2021)

What Causes Desmoplastic Reaction in Small Intestinal Neuroendocrine Neoplasms?
por: Ratnayake, Gowri M., et al.
Publicado: (2022)

Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors
por: Gubbi, Sriram, et al.
Publicado: (2022)

Clinical implications of immune checkpoint markers and immune infiltrates in patients with thymic neuroendocrine neoplasms
por: Liu, Man, et al.
Publicado: (2022)

Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?
por: Gravara, Luigi Della, et al.
Publicado: (2020)

The Role of Patient Support Groups in Neuroendocrine Neoplasms
por: Kolarova, Teodora, et al.
Publicado: (2021)

The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't
por: Malek, Alexandre E, et al.
Publicado: (2021)

Inflammation-related cytokines and their roles in gastroenteropancreatic neuroendocrine neoplasms
por: Mahečić, Davorka Herman, et al.
Publicado: (2020)

Role of Endoscopic Ultrasound in the Diagnosis of Pancreatic Neuroendocrine Neoplasms
por: Ishii, Tatsuya, et al.
Publicado: (2021)

The Role of the Microbiome in Gastroentero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs)
por: Mohamed, Amr, et al.
Publicado: (2022)

The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?
por: Cummings, Amy L., et al.
Publicado: (2017)

Checkpoint inhibitor-induced hepatotoxicity: Role of liver biopsy and management approach
por: Bessone, Fernando, et al.
Publicado: (2022)

The Use of PDX1 DNA Methylation to Distinguish Two Subtypes of Pancreatic Neuroendocrine Neoplasms with Different Prognoses
por: Ungefroren, Hendrik, et al.
Publicado: (2022)

Histopathology of gastrointestinal neuroendocrine neoplasms
por: Hirabayashi, Kenichi, et al.
Publicado: (2013)

Imaging of Pancreatic Neuroendocrine Neoplasms
por: Chiti, Giuditta, et al.
Publicado: (2021)

Neuroendocrine Neoplasms of the Gynecologic Tract
por: Virarkar, Mayur, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q1l1jhjnb0c2gh7qphqop5q4nm